These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 20683668

  • 1. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy.
    Stein P, Malhotra A, Haims A, Pastores GM, Mistry PK.
    J Inherit Metab Dis; 2010 Dec; 33(6):769-74. PubMed ID: 20683668
    [Abstract] [Full Text] [Related]

  • 2. Splenic nodules in paediatric Gaucher disease treated by enzyme replacement therapy.
    Chippington S, McHugh K, Vellodi A.
    Pediatr Radiol; 2008 Jun; 38(6):657-60. PubMed ID: 18379770
    [Abstract] [Full Text] [Related]

  • 3. Improvement of life quality measured by Lansky Score after enzymatic replacement therapy in children with Gaucher disease type 1.
    Cerón-Rodríguez M, Barajas-Colón E, Ramírez-Devars L, Gutiérrez-Camacho C, Salgado-Loza JL.
    Mol Genet Genomic Med; 2018 Jan; 6(1):27-34. PubMed ID: 29471591
    [Abstract] [Full Text] [Related]

  • 4. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
    Hollak CE, Belmatoug N, Cole JA, Vom Dahl S, Deegan PB, Goldblatt J, Rosenbloom B, van Dussen L, Tylki-Szymańska A, Weinreb NJ, Zimran A, Cappellini MD.
    Br J Haematol; 2012 Aug; 158(4):528-38. PubMed ID: 22640238
    [Abstract] [Full Text] [Related]

  • 5. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
    Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A.
    Am J Med; 2002 Aug 01; 113(2):112-9. PubMed ID: 12133749
    [Abstract] [Full Text] [Related]

  • 7. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N.
    Am J Hematol; 2017 Sep 01; 92(9):929-939. PubMed ID: 28569047
    [Abstract] [Full Text] [Related]

  • 8. Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I.
    Gras-Colomer E, Martínez-Gómez MA, Climente-Martí M, Fernandez-Zarzoso M, Almela-Tejedo M, Giner-Galvañ V, Marcos-Rodríguez JA, Rodríguez-Fernández A, Torralba-Cabeza MÁ, Merino-Sanjuan M.
    Basic Clin Pharmacol Toxicol; 2018 Jul 01; 123(1):65-71. PubMed ID: 29418074
    [Abstract] [Full Text] [Related]

  • 9. Haemostatic abnormalities in treatment-naïve patients with Type 1 Gaucher's disease.
    Mitrovic M, Antic D, Elezovic I, Janic D, Miljic P, Sumarac Z, Nikolic T, Suvajdzic N.
    Platelets; 2012 Jul 01; 23(2):143-9. PubMed ID: 21767238
    [Abstract] [Full Text] [Related]

  • 10. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators.
    Mol Genet Metab; 2021 Feb 01; 132(2):100-111. PubMed ID: 33485799
    [Abstract] [Full Text] [Related]

  • 11. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
    Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ.
    Br J Haematol; 2009 Nov 01; 147(4):561-70. PubMed ID: 19732054
    [Abstract] [Full Text] [Related]

  • 12. Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study.
    Zimmermann A, Grigorescu-Sido P, Rossmann H, Lackner KJ, Drugan C, Al Khzouz C, Bucerzan S, Naşcu I, Zimmermann T, Leucuţa D, Weber MM.
    J Inherit Metab Dis; 2013 May 01; 36(3):555-63. PubMed ID: 22976766
    [Abstract] [Full Text] [Related]

  • 13. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
    Zimran A, Wang N, Ogg C, Crombez E, Cohn GM, Elstein D.
    Am J Hematol; 2015 Jul 01; 90(7):577-83. PubMed ID: 25903392
    [Abstract] [Full Text] [Related]

  • 14. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 01; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 15. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
    Laudemann K, Moos L, Mengel E, Lollert A, Hoffmann C, Brixius-Huth M, Wagner D, Düber C, Staatz G.
    Blood Cells Mol Dis; 2016 Mar 20; 57():35-41. PubMed ID: 26852653
    [Abstract] [Full Text] [Related]

  • 17. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
    Hurvitz N, Dinur T, Becker-Cohen M, Cozma C, Hovakimyan M, Oppermann S, Demuth L, Rolfs A, Abramov A, Zimran A, Revel-Vilk S.
    Int J Mol Sci; 2019 Jun 21; 20(12):. PubMed ID: 31234327
    [Abstract] [Full Text] [Related]

  • 18. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Jun 21; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 19. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A.
    Am J Hematol; 2013 Mar 21; 88(3):166-71. PubMed ID: 23386328
    [Abstract] [Full Text] [Related]

  • 20. Retrospective Analysis of Whole-Body Magnetic Resonance Imaging of Bone Manifestations in Long-Term Treated Patients with Gaucher Disease Type 1.
    Lollert A, Laudemann K, Mengel E, Hoffmann C, Moos L, Reinke J, Brixius-Huth M, Hennermann JB, Düber C, Staatz G.
    Klin Padiatr; 2019 Mar 21; 231(2):52-59. PubMed ID: 30481833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.